Reporter brief
SIRT6 activator MDL-800 reduced osteoarthritis severity in aging mice given monthly injections.
What happened
Male mice aged 18 months received weekly intraperitoneal injections of MDL-800 (a SIRT6 activator) or vehicle for 6 months, then were assessed for osteoarthritis at 24 months. MDL-800-treated mice showed less cartilage damage, osteophyte formation, bone sclerosis, and meniscal ossification compared to controls. Mechanistic studies in cultured human chondrocytes showed MDL-800 suppressed catabolic signaling pathways and reduced DNA damage.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Animal; Animal.
Male 18-month-old mice
- Design
- Animal
- Sample
- —
- Journal
- Arthritis & rheumatology (Hoboken, N.J.)
- Published
- Sep 22, 2026
Effect size
Not recorded.
Caveats
- Assessment: Pending.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Gene therapy for ageing timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.